InTRoduCTIon
Early cytological diagnosis and treatment of high-grade squamous intraepithelial lesions (HSiL) play a critical role in protection from cervical cancer. Smears with cells that are suspicious though not diagnostic for HSiL and no squamous intraepithelial lesion in the background were included in the Bethesda System in 2001 as 'atypical squamous cells where HSiL cannot be excluded' (aSH-C) as it has been shown to be effective in the histopathological determination of HSiL cases during follow-up (1) . However, some smears encountered during the daily routine contain cells that are not diagnostic but suspicious regarding HSiL in addition to marked low-grade squamous intraepithelial lesion (LSiL) findings in the background. These cases are Cilt/Vol. 27, No. 1, 2011; Sayfa/Page 46-50 frequently reported as LSiL/aCH or LSiL where HSiL cannot be excluded (LSiL-H). recent studies have found the rate of a cervical intraepithelial lesion 2 (Cin2) or higher diagnosis in these biopsy materials to be higher than those that received a diagnosis of LSiL only (2) (3) (4) (5) (6) (7) (8) (9) . This rate is seen to be similar to that of receiving a diagnosis of Cin2 or above on histopathology for patients with a diagnosis of aSC-H. We aimed to compare the LSiL/aSC-H diagnosis and LSiL-aSC-H, HSiL diagnosis in conventional Pap smears and to evaluate the clinical significance of these results especially for LSiL/aSC-H in this study.
MATeRIAl and MeThod
The smears that had received a diagnosis of aSC-US, LSiL, aSC-H, LSiL/aSC-H, or HSiL among the 37884 conventional Pap smears screened at our hospital between January 2005 and December 2009 were re-evaluated and a total of 153 patients who had undergone a biopsy within one year after the Pap smear were included in the study. The dysplasia with the highest degree was recorded from the biopsy results in cases that had undergone multiple biopsies. The results were classified under 5 histopathological diagnoses as benign, Cin1, Cin2, Cin3 and cancer. a LSiL/aSC-H diagnosis was made in smears with aSC-H changes among an LSiL appearance ( Figure 1 ). The following cytomorphological results were used in defining aSC-H cells, based on previously reported studies (9-11); (1) the presence of usually 5 or less dysplastic cells with HSiL-like findings, (2) the presence of atypical metaplastic squamous cells, (3) the presence of cells with an n/C ratio between LSiL and HSiL ( Figure 2 ).
The biopsy result distribution between the groups was analyzed by using only SiL cases (a total of 153) to calculate the positive predictive value (PPV).
ReSulTS
We found that 37884 conventional Pap smears screened between 2005 and 2009 had been reported as follows: ' atypical squamous cells of unknown importance' (aSC-US) 1.2% (461 cases), LSiL 0.15% (57 cases), aSC-H 0.06% (25 cases), LSiL/aSC-H 0.10% (40 cases), HSiL 0.08% (31 cases), HSiL+ invasive carcinoma not excluded 0.02% (10 cases), atypical glandular cells (aGC) 0.02% (10 cases), squamous cell carcinoma (SCC) 0.05% (19 cases), and adenocarcinoma 0.01% (4 cases) ( Table i ).
The total rate of atypical cytology as diagnosed by a conventional Pap smear was 1.69% (657 cases).
The percentages of preinvasive cervical neoplasms and invasive neoplasms were 1.63% and 0.06%, respectively.
There were a total of 371 (56%) cases that had received a diagnosis of atypical cytology by Pap smear with a histopathological lesion on biopsy. These cases were distributed as Cin 1 in 47% (175 cases), Cin 2 in 28% (103 cases), Cin 3 in 19% (80 cases) and invasive cancer in 6% (23 cases) (Table ii) .
We found that the percentage of cases which underwent a biopsy within a year after Pap smear was 17.5% (10 cases) for LSiL, 48% (12) for aSC-H, 50% (20 cases) for LSiL/ aSC-H and 74% (23 cases) for HSiL.
1. a Cin2 or higher lesion had been found in 45% of LSiL/ aSC-H cases (PPV=45%). This rate was higher than for LSiL cases (10%, PPV=10%), similar to aSC-H cases (50%, PPV=50%) and lower than for HSiL cases (65%, PPV=65%) (Table iii ). 2. Classifying high-grade intraepithelial neoplasms as moderate (Cin2) or severe (Cin3) and higher, we found a Cin3 or higher lesion in 15% of biopsies from LSiL/ aSC-H cases. This rate was similar to LSiL cases (10%) and lower than in aSC-H (42%) and HSiL (52%) cases.
3. The rate of Cin2 in the biopsies was 30% in the LSiL/ aSC-H group. This rate was higher than in LSiL (0%), aSC-H (8%) and HSiL (13%).
4. The rate of Cin1 in the biopsies was 35% for LSiL/aSCH cases. This rate was higher than in the LSiL group (70%), similar to the aSC-H group (33%) and higher than in the HSiL group (10%).
5. We found no significant difference between the benign diagnosis rates in cases with an LSiL/aSC-H diagnosis (20%) and the other groups (LSiL 20%, aSC-H 17%, HSiL 26%).
our results showed that Cin2 rate was higher in the biopsies of the LSiL/aSC-H group compared to the aSC-H and HSiL groups; Cin3 rate was lower than the aSC-H and HSiL groups, and Cin2 or higher lesion rate was similar to the aSC-H group but lower than the HSiL group. The rate of Cin1 was lower than in the LSiL group. our total cytological abnormality rate was 1.69% and this was similar to another study from Turkey on the prevalence of cervical cytological abnormalities (1.8%) (12) . our LSiL/aSC-H ratio (0.10%) was close to that of other authors (0.15-0.53%) (3, 5, 6 ).
The rate of diagnosing a Cin2 or higher grade lesion on biopsy following an LSiL/aSC-H diagnosis (45%) was similar to aSC-H (50%), higher than for LSiL (10%) and lower than for HSiL (65%). These results were consistent with recent publications. The potential of LSiL/aSC-H to catch a Cin2 or higher lesion (45%) was especially consistent with some previous studies (3, 6, 16, 17) . The rate of finding a Cin2 or higher lesion in LSiL/aSC-H biopsies was slightly higher than aSC-H in some studies (4, 6, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) and slightly lower in others (2,3,5,19).
We found a 15% rate for LSiL/aSC-H to define a Cin3 or higher lesion in biopsy results, similar to Difurio et al. ). This rate was markedly lower than with aSC-H (42%) and HSiL (52%).
The Cin2 detection rate of patients with an LSiL/ aSC-H diagnosis was 30% on follow-up. This rate was higher than with LSiL (0%), aSC-H (8%) and HSiL (13%). Hang et al. (18) and alsharif et al (8) . have also reported that biopsies of patients diagnosed with LSiL/aSC-H have a higher rate of Cin2 diagnosis when found to have a Cin2 or higher lesion and LSiL/aSC-H probably indicates Cin2 as also reported by these authors.
The rate of receiving a diagnosis of Cin1 was 30% in the LSiL/aSC-H group, 70% for LSiL, 33% for aSC-H and 10% for HSiL. We found the rate of determining the Cin1 diagnosis for the LSiL/aSC-H group to be markedly lower than LSiL. our results were consistent with previous studies (33.73%).
We obtained similar values between aSC-H, and LSiL and HSiL as regards determining Cin2 or higher lesions of LSiL-aSC-H. Past studies have reported similar results (2, 8, 16 in conclusion, we believe that LSiL/aSC-H should be classified as a separate category as there is a high chance of defining the underlying Cin2 and that it should therefore be evaluated separately from LSiL. We found that LSiL/ aSC-H had a high risk of a Cin2 or higher neoplasia like aSC-H but that it had low risk for Cin3 in contrast. The clinical management of Cin2 and Cin3 is similar and the clinical approach to LSiL/aSC-H should be undertaken keeping in mind that it can act like aSC-H.
